89bio (ETNB) Stock Forecast, Price Target & Predictions
ETNB Stock Forecast
89bio stock forecast is as follows: an average price target of $22.00 (represents a 151.14% upside from ETNB’s last price of $8.76) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
ETNB Price Target
The average price target for 89bio (ETNB) is $22.00 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $29.00 to $12.00. This represents a potential 151.14% upside from ETNB's last price of $8.76.
ETNB Analyst Ratings
According to 8 Wall Street analysts, 89bio's rating consensus is 'Buy'. The analyst rating breakdown for ETNB stock is 1 'Strong Buy' (12.50%), 6 'Buy' (75.00%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
89bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 06, 2024 | Brian Abrahams | RBC Capital | - | - | 49.44% | 36.99% |
| Jun 07, 2024 | Eliana Merle | UBS | - | - | 208.64% | 185.39% |
| May 10, 2024 | Ed Arce | H.C. Wainwright | - | - | 222.22% | 231.05% |
The latest 89bio stock forecast, released on Aug 06, 2024 by Brian Abrahams from RBC Capital, set a price target of $12.00, which represents a 49.44% increase from the stock price at the time of the forecast ($8.03), and a 36.99% increase from ETNB last price ($8.76).
89bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 3 |
| Avg Price Target | - | - | $22.00 |
| Last Closing Price | $8.76 | $8.76 | $8.76 |
| Upside/Downside | -100.00% | -100.00% | 151.14% |
In the current month, the average price target of 89bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to 89bio's last price of $8.76. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 06, 2024 | Raymond James | Strong Buy | Strong Buy | Hold |
| Aug 06, 2024 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jun 07, 2024 | UBS | Buy | Buy | Hold |
| May 14, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jul 03, 2023 | BTIG | Buy | Buy | Hold |
| Mar 23, 2023 | Raymond James | Strong Buy | Strong Buy | Hold |
| Feb 21, 2023 | Oppenheimer | Outperform | Outperform | Hold |
| Nov 11, 2022 | RBC Capital | Outperform | Outperform | Hold |
| Sep 13, 2022 | Raymond James | Strong Buy | Strong Buy | Hold |
89bio's last stock rating was published by Raymond James on Aug 06, 2024. The company gave ETNB a "Strong Buy" rating, the same as its previous rate.
89bio Financial Forecast
89bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | $625.00K | $750.00K | - |
| High Forecast | - | - | - | - | $625.00K | $750.00K | - |
| Low Forecast | - | - | - | - | $625.00K | $750.00K | - |
| # Analysts | - | - | - | - | 7 | 3 | - |
| Surprise % | - | - | - | - | - | - | - |
89bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ETNB's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
89bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 7 | 3 | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict ETNB's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than 89bio's previous annual EBITDA (undefined) of $NaN.
89bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 7 | 3 | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-73.74M | $-70.22M | $-70.21M | $-71.53M | $-80.84M | $-66.77M | $-56.35M |
| High Forecast | $-73.74M | $-70.22M | $-70.21M | $-67.66M | $-57.30M | $-66.77M | $-56.35M |
| Low Forecast | $-73.74M | $-70.22M | $-70.21M | $-74.43M | $-105.39M | $-66.77M | $-56.35M |
| Surprise % | - | - | - | - | - | - | - |
89bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ETNB's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
89bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 7 | 3 | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
89bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to ETNB last annual SG&A of $NaN (undefined).
89bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 7 | 3 | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.69 | $-0.66 | $-0.66 | $-0.67 | $-0.75 | $-0.62 | $-0.56 |
| High Forecast | $-0.69 | $-0.66 | $-0.66 | $-0.63 | $-0.54 | $-0.62 | $-0.56 |
| Low Forecast | $-0.69 | $-0.66 | $-0.66 | $-0.70 | $-0.98 | $-0.62 | $-0.56 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, 89bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ETNB previous annual EPS of $NaN (undefined).
89bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | - | - | 10506.06% | Buy |
| XFOR | X4 Pharmaceuticals | - | - | 979.41% | Buy |
| INZY | Inozyme Pharma | - | - | 422.06% | Buy |
| PLRX | Pliant Therapeutics | - | - | 205.93% | Buy |
| ABOS | Acumen Pharmaceuticals | - | - | 195.36% | Buy |
| DAWN | Day One Biopharmaceuticals | - | - | 182.80% | Buy |
| STOK | Stoke Therapeutics | - | - | 167.72% | Buy |
| ETNB | 89bio | - | - | 151.14% | Buy |
| TERN | Terns Pharmaceuticals | - | - | 146.11% | Buy |
| VKTX | Viking Therapeutics | - | - | 94.71% | Buy |
| MREO | Mereo BioPharma Group | - | - | 81.45% | Buy |
| AKRO | Akero Therapeutics | - | - | 40.54% | Buy |
| HOOK | HOOKIPA Pharma | - | - | 39.53% | Buy |
| ACLX | Arcellx | - | - | -8.23% | Buy |
| MDGL | Madrigal Pharmaceuticals | - | - | -9.12% | Buy |
| TGTX | TG Therapeutics | - | - | -21.30% | Buy |